

# Chromatin modification and disease

Colin A Johnson

*"Physicians consider that when they have discovered the cause of disease, they have also discovered the method of treating it."* Cicero, Tusculan Disputations, III.x.23.

In the last few years, the exciting realisation in the field of gene regulation is that transcription factors can function by recruiting large, multiprotein complexes which mediate several types of chromatin modification and remodelling events that alter the structure of chromatin. Chromatin structure changes include post-translational modifications of histones, DNA methylation, remodelling of the chromatin, and the maintenance of a heterochromatic or euchromatic state. Most of these events are brought about by enzymatic mechanisms. In general, the catalytic subunits are only one component of the complexes, with the distribution and localisation of the structural changes dependent on targeting components. Many of the catalytic components (sometimes called coactivators and corepressors) interact with the activator and repressor proteins that mediate the actual process of transcriptional regulation. Transcriptional dysregulation can therefore arise from mutations that cause the loss or perturbation of chromatin modification or remodelling, which are now known to have an important role in the pathogenesis of cancer and other genetic diseases. Some of the proteins that mediate these events are therefore novel molecular targets for future treatments.

In eukaryotes, DNA is packaged by histone proteins into nucleosomes, the fundamental repeating structural unit of chromatin.<sup>1</sup> The nucleosomal core particle consists of an octameric complex of core histones (two each of H2A, H2B, H3, and H4) around which 147 bp of DNA is wrapped in 1.65 turns of a left handed superhelix.<sup>2</sup> The minor and major grooves of adjacent turns of the DNA superhelix line up and form channels through which the histone N-terminal domains protrude from the core. These regions are in the form of "tails" that appear to lack secondary structure<sup>3</sup> and are subject to various enzyme catalysed, post-translational modifications which affect their charge and can influence the degree of chromatin compaction. The tightness with which DNA is packaged into chromatin will limit the binding and function of proteins that mediate transcriptional regulation, and this will therefore influence the transcriptional competence of any given gene in such a chromatin environment.<sup>2,4</sup>

Covalent post-translational acetylation and deacetylation of specific lysine residues in the histone N-terminal is one of the most widely studied chromatin modifications. In the past four years there have been rapid advances in identifying the enzymes and multiprotein com-

plexes that bring about histone acetylation (the family of histone acetyltransferases or HAT coactivators) and deacetylation (the histone deacetylases or HDAC corepressors). This review will focus on some of the clinical aspects of this recent work on acetylation and the intimate connection that it is now known to have with the methylation of cytosine residues in DNA. A third type of chromatin remodelling is the direct physical repositioning or disruption of nucleosomes mediated by a family of DNA dependent ATPases. The connection between this latter type of remodelling and either histone acetylation or DNA methylation is complicated, but progress is being made. For example, the NuRD multiprotein complex (see below, fig 1C) contains histone deacetylase and chromatin remodelling activities, as well as the methyl DNA binding protein MBD3, which suggests that a profound interplay between these modifications is required during gene regulation. Therefore, it is probable that a particular pathogenesis may be caused by defects in more than one type of chromatin modification. Relevant pathologies and syndromes are discussed in following sections and are summarised in table 1.

## Histone acetylation, protein acetylation, and gene regulation


### HISTONE DEACETYLASES AND COREPRESSOR COMPLEXES

Deacetylation of histones is, in general, associated with repression of gene transcription, presumably because the highly positively charged N-terminal tails of the core histones can now interact with DNA on the nucleosome surface and in the linker DNA.<sup>5,6</sup> In addition, the positively charged lysines in the H4 tail may interact with the negative face of an H2A-H2B dimer from a neighbouring nucleosome,<sup>7</sup> and hence bring about further compaction of the chromatin. Deacetylation is brought about by the action of the histone deacetylases (HDACs), which would therefore enhance histone-histone interactions by maintaining the positively charged (unmodified) state of lysines in the histone tails. HDACs are now known to be corepressor components of many multiprotein complexes that modify and remodel chromatin.

Targeting of complexes containing HDAC1 and HDAC2 is achieved by the interaction of the repressor proteins Sin3A, Sin3B,<sup>8</sup> and other Sin3 associated proteins (SAPs)<sup>9</sup> in a large multiprotein complex that comprises at least seven subunits<sup>10</sup> (fig 1A). The mammalian Sin3 complex mediates repression for an extensive and ever growing list of transcriptional regulator proteins,<sup>8,10,11</sup> which include DNA binding components such as the Mad/

**Chromatin and Gene Expression Group,  
Department of Anatomy, University of Birmingham,  
Birmingham B15 2TT,  
UK**

Correspondence to:  
Dr Johnson,  
c.a.johnson@bham.ac.uk




**Figure 1** Schematic representation of multiprotein complexes that mediate chromatin modifications. Some of the known components of the complexes are shown on the left, with arrows indicating additional interactions with other proteins on the right (refer to main text for details). Histone deacetylases (HDAC) are shown in purple, components of the DNA methylation system in yellow, and ATPase/helicase that mediates chromatin remodelling in green. Other corepressor accessory proteins in the complexes (panels A-C) are shown in grey. (A) Components of the HDAC/Sin3 complex and known interacting proteins. (B) Additional interactions of the HDAC/Sin3 complex, mediated by the corepressors NCoR/SMRT, with unliganded nuclear receptors and leukaemogenic fusion proteins. Note that these interactions occur at low concentrations, or in the absence of the receptor ligand. (C) Components and interactions of the NuRD complex.

Max heterodimer and nuclear hormone receptors (see below, fig 1B). The members of the Mad/Mxi1 family<sup>12</sup> are able to replace Myc in the Myc/Max heterodimer, and can therefore repress transcription at promoters with Myc consensus DNA binding sites. Mutations in the Sin3 interaction domains (SIDs) of Mad/Mxi1 can abolish binding of the corepressors to the Sin3 proteins and hence HDACs, and this correlates with the abolition of transcriptional repression and anti-oncogenic activity.<sup>13</sup> In addition, transfection studies have shown that HDACs and Mad cooperate to repress cell proliferation.<sup>14</sup> In a similar mechanism, the transcriptional corepressor proteins N-CoR (nuclear hormone receptor corepressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptor) target deacetylase activity to non-liganded thyroid hormone and retinoic acid nuclear receptors<sup>15-17</sup> and to antagonist bound oestrogen and progesterone receptors.<sup>18</sup> As discussed below, the presence of receptor ligands, for example, retinoic acid,

appears to induce an exchange of the corepressor complexes containing HDACs for those with coactivator functions that contain histone acetyltransferase (HAT) activities<sup>18, 19</sup> (compare figs 1B and 2A).

Histone deacetylases are also recruited by the retinoblastoma protein pRb<sup>20</sup> (fig 1A), the product of a tumour suppressor gene, and an inhibitor of cell proliferation.<sup>21</sup> The inhibitory action of pRb is the result, in part, of its ability to bind to the E2F family of DNA binding transcription factors, which results in the sequestration of E2F and repression of E2F target genes during the G1 phase of the cell cycle.<sup>22</sup> The interaction is mediated by the A/B pocket domain in pRb, and it is no coincidence that the great majority of Rb mutations in human tumours are located in this domain. The pocket domain can also interact with a variety of other cellular proteins, including viral transforming oncoproteins (such as E1A from adenovirus and SV40 large T<sup>23</sup>) and histone deacetylases (HDAC1 and HDAC2) that share the common LXCXE motif which allows interactions with pocket proteins. However, the interaction between Rb and either HDACs or viral oncoproteins appears to be competitive, and the Rb-HDAC1 interaction may be one of the intracellular targets for these transforming proteins. The Rb-HDAC interaction has been analysed by transient transfection experiments, which show that Rb and the HDACs cooperate in repressing an E2F1-driven promoter,<sup>24-26</sup> and the repression exerted by Rb and other pocket proteins during the G1 phase of the cell cycle<sup>27</sup> can be reversed by treatment with chemical inhibitors of HDACs (see below). The HDAC inhibitors can also upregulate some of the E2F target genes.<sup>24</sup> It is probable that aberrant targeting of deacetylase activity and incorrect chromatin remodelling are one step in the process of transformation and implies that these processes have a fundamental role in the suppression of carcinogenesis. In



**Figure 2** Schematic representation of interactions mediated by histone acetyltransferases (HATs). Unbroken arrows indicate known interactions of HATs with the proteins listed on the right (refer to main text for details). Histone acetyltransferases are shown in red, the SWI/SNF complex that mediates chromatin remodelling in green, and other accessory proteins in grey. (A) Interactions of three human histone acetyltransferases. The p300/CBP coactivator can interact with nuclear receptors at physiological concentrations of the receptor ligand, with other transcription factors and with the histone acetyltransferase PCAF. PCAF can also interact with the coactivator ACTR and transcription factors. (B) Putative interactions of the human and/or yeast Hat1 protein with both RbAp48 and, through the bromodomain, with histones H3 and H4. Histone H4 can also interact directly with both RbAp46 and RbAp48. The bromodomain may also mediate an interaction with the yeast SWI/SNF complex (broken arrow).

the case of pRb, histone modification is implicated in the induction of cell cycle arrest which may explain why the *Rb* gene is mutated in almost all cancer cells.

In addition to E2F and HDACs, Rb has also been shown to interact with other proteins that regulate chromatin modifications: TAFII 250 is a transcription factor that has intrinsic histone acetyltransferase (HAT) activity<sup>28</sup>; BRG1 is a transcriptional activator and ATPase/helicase that is a component of the mammalian SWI/SNF chromatin remodelling complex<sup>29</sup>; and Rb associated protein 48 (RbAp48) is a component of the chromatin assembly factor CAF-1,<sup>30</sup> interacts with HDAC1,<sup>31</sup> and is a component of the human Hat1 acetyltransferase<sup>32</sup> (fig 2B). RbAp48, and the related protein RbAp46, can bind directly to an alpha helix in histone H4,<sup>32</sup> so it is likely that these proteins mediate core histone binding for the Sin3-HDAC complex, CAF-1 and Hat1.

A similar network of interactions that regulate cell proliferation is also seen with the HATs (see below) and for histone deacetylase complexes other than the Sin3-HDAC complex. For example, a novel multiprotein complex has been isolated recently that contains both nucleosome remodelling and histone deacetylase activities (hence the NuRD complex,<sup>33</sup> fig 1C). The NuRD complex contains, in addition to HDAC1 and HDAC2, the dermatomyositis specific autoantigen Mi-2 $\beta$ <sup>34</sup> that contains an ATPase/helicase domain of the SWI/SNF type (see below). In addition, the NuRD complex contains a protein, MTA2,<sup>35</sup> that is homologous to the metastasis associated protein MTA1,<sup>36</sup> which is expressed at high levels in several human cancer cell lines and tissues. The NuRD complex can also be recruited to DNA by specific DNA binding factors, in a similar mechanism to the targeting of the Sin3-HDAC complex. For example, two determinants of the lymphoid lineage in T cells, Ikaros and Aiolos, have been shown to associate with the NuRD complex.<sup>37</sup> However,

Ikaros and Aiolos can also function as transcriptional repressors during lymphocyte development by recruiting the Sin3-HDAC complex.<sup>38</sup>

#### HISTONE DEACETYLASES AND LEUKAEMOGENIC FUSION PROTEINS

The interaction of HDACs with chimeric mutant proteins of the retinoic acid receptor is one of the mechanisms that underlies the molecular pathogenesis of acute promyelocytic leukaemia (APL),<sup>39, 40</sup> one of the best characterised forms of acute myeloid leukaemia (AML).<sup>41</sup> In this disease, chromosomal translocations create fusion proteins of retinoic acid receptor- $\alpha$  and either PML (for promyelocytic leukaemia) or, in rare cases, PLZF (for promyelocytic leukaemia zinc finger).<sup>42, 43</sup> In the case of PML/RAR- $\alpha$  forms of APL, the fusion protein retains the ability of the wild type nuclear receptor to recruit the N-CoR/HDAC complex (fig 1B) and to block haematopoietic differentiation. However, physiological concentrations of retinoic acid dissociate the corepressor complex from wild type RAR- $\alpha$  (see above and fig 2A), so that it can therefore function as a transcriptional activator. In contrast, the fusion protein retains the ability to bind to the corepressor complex under these conditions, thereby constitutively repressing RAR- $\alpha$  target genes. Treatment with higher, pharmacological concentrations of the hormone overcomes this interaction and converts the PML/RAR- $\alpha$  fusion protein back into an activator. As a consequence, cell proliferation is inhibited and neutrophilic differentiation of neoplastic cells is induced, which is the basis of differentiation therapy of APL.<sup>42</sup> One of the target genes of PML/RAR- $\alpha$  during RA induced differentiation of APL cells is that encoding the cyclin-CDK inhibitor p21<sup>44</sup> (also known as WAF1 and CIP1), which exerts a G1 cell cycle arrest in response to a variety of stimuli.<sup>45</sup>

In contrast, cells expressing the PLZF/RAR- $\alpha$  fusion are not sensitive to RA induced differentiation, and patients with this type of

*Table 1 Summary of human diseases in which a defect in chromatin modification and remodelling is believed to contribute to a clinical pathology. The defects can arise from mutations in gene products, or by the aberrant recruitment of other proteins that are components of multiprotein complexes. Refer to the main text for details*

Type of chromatin modification	Enzymes and other proteins that mediate the chromatin modification	Mutated genes implicated as a cause of a pathogenesis	Relevant proteins that interact with the enzymes etc	Clinical conditions and pathologies that correlate with a listed mutation or protein-protein interaction	References	
Histone acetylation	Histone deacetylases HDAC1/2	<i>Rb</i>	pRb	Neoplasia	24, 25, 26	
		<i>p53</i>	p53	Neoplasia	92	
		—	Mi-2 $\beta$	Dermatomyositis and neoplasia	33, 34, 122	
		—	MTA2	Metastasis	35	
	Histone acetyltransferases p300/CBP	<i>RAR<math>\alpha</math></i>	Fusion proteins	Acute promyelocytic leukaemia	39, 40, 47, 48	
		—	E1A	Transformation	82	
Histone phosphorylation	TAF II 250	<i>MLL</i> and <i>MOZ</i>	Fusion proteins	Acute myeloid leukaemia	94, 95	
		<i>CBP</i>	—	Rubinstein-Taybi syndrome	96	
	Rsk-2 kinase	—	pRb	Loss of tumour suppression?	28	
	DNA methylation	<i>DNMT3B</i>	Not known	Coffin-Lowry syndrome	103	
	DNA methylation	MethylCpG binding proteins	<i>MECP2</i>	HDAC/Sin3	ICF syndrome	113, 114
			<i>MBD4</i>	Not known	Rett syndrome	125
Chromatin remodelling	ATPase/helicases Mi-2 $\beta$	—	Not known	Microsatellite unstable colon cancers	124	
		<i>ATRAX</i>	NuRD complex	Dermatomyositis and neoplasia	130, 131	
	BRG-1/hBRM	—	Not known	ATRAX syndrome	134	
	hSWI5/INI1 subunit of SWI2/SNF2 complex	—	pRb	Neoplasia	28	
		<i>hSWI5/INI1</i>	SWI2/SNF2 complex	Malignant rhabdoid tumours, chronic myeloid leukaemias	141, 142	

APL respond poorly, if at all, to pharmacological doses of the hormone.<sup>46</sup> The interaction between PLZF/RAR- $\alpha$  and the corepressor complex is resistant to retinoic acid because the wild type PLZF protein can itself interact directly with corepressors such as SMRT and N-CoR.<sup>39 40 47</sup> This interaction is mediated by the broad complex/tramtrack/bric a brac/poxviruses and zinc finger (BTB/POZ) repression domain from PLZF,<sup>48</sup> which also allows SMRT to interact with another BTB/POZ oncoprotein, LAZ3/BCL6.<sup>49</sup> In contrast, other transcriptional repressors that also contain the BTB/POZ domain, such as the product of the putative tumour suppressor gene *HIC-1* (for hypermethylated in cancer), do not recruit the SMRT/N-CoR-histone deacetylase complex as a general mechanism to repress transcription.<sup>50</sup> However, since HDAC inhibitors restore the retinoid responses of RA resistant APL cell lines,<sup>39</sup> clinical and cytogenetic remission of a PLZF/RAR- $\alpha$  type of APL has been achieved with a combination therapy of retinoic acid and phenylbutyrate, an HDAC inhibitor.<sup>51</sup> Such combination therapies may therefore be applicable to other types of neoplastic diseases that are associated with oncogenic repression of gene transcription by histone deacetylases.

#### HISTONE DEACETYLASE INHIBITORS AND CANCER CHEMOTHERAPY

Inhibitors of HDACs have also received considerable attention as possible therapeutic agents to induce growth arrest and terminal differentiation in malignant cells and therefore prevent the progression of cancers. HDAC inhibitors can be classified on the basis of structure and mode of inhibition. Reversible inhibitors include *n*-butyric acid and other related short chain fatty acids,<sup>52 53</sup> the microbial antibiotic trichostatin A (TSA<sup>54</sup>), and hybrid polar compounds such as suberoylanilide hydroxamic acid (SAHA<sup>55</sup>). The carboxylic and hydroxamic acid groups in this set of compounds are likely to be specific ligands of a catalytic zinc ion at the active site of HDAC<sup>55 56</sup> because a similar zinc binding site exists in a prokaryotic homologue of the enzyme.<sup>57</sup> Irreversible inhibitors include trapoxin<sup>58 59</sup> and trapoxin related natural products, such as chlamydocin and HC toxin.<sup>60</sup> These compounds are tetrapartite cyclic peptides with 2-amino-9,10-epoxy-8-oxodecanoic acid (Aeo) as one residue. Aeo contains an epoxyketone group that is isosteric with *N*-acetyl lysine and is presumed to inhibit HDACs by binding covalently and irreversibly to nucleophilic groups in the active site of the enzymes. TSA, trapoxin, and depudicin (a fungal metabolite that resembles Aeo<sup>61</sup>) have all been shown to revert the morphologies of oncogene transformed cells and cells derived from tumours to those with a normal cytoskeletal architecture.<sup>58 61 62</sup> TSA and SAHA are also potent inducers of transformed cell differentiation and apoptosis.<sup>55 63</sup> A novel antibiotic and HDAC inhibitor, FR901228,<sup>64</sup> can strongly inhibit proliferation of tumour cells in vitro by arresting cell cycle transition at G1 and G2/M phases, a property that is common between the

unrelated types of HDAC inhibitors.<sup>65</sup> For this reason, HDAC inhibitors are being assessed as therapeutic agents for cancer chemotherapy<sup>66</sup> and as adjuncts to established agents such as retinoic acid (see above). In view of this, it is interesting to note that *n*-butyric acid causes growth inhibition, differentiation, and apoptosis in colon cancer derived cell lines.<sup>67</sup> Butyrate is a natural fermentation product of certain dietary fibres by anaerobic bacteria in the lumen of the colon. The production of this short chain fatty acid may be the key factor that allows dietary fibre, for example fibre from wheat, to protect against colon carcinogenesis. The molecular mechanism that underlies this protection is presumed to be inhibition of histone deacetylase activity and induction of histone hyperacetylation by butyrate.<sup>68</sup> Archer *et al*<sup>68</sup> showed that butyrate induces expression of the G1 cell cycle inhibitor *p21* gene (see above), presumably in response to hyperacetylation of the *p21* promoter, which induces growth arrest in colonic cancer cells. Trapoxin has also been shown to increase *p21* expression in human tumour cells, with an increase of histone H3 acetylation at the *p21* promoter and the induction of apoptosis in a cell line that contained wild type p53.<sup>69</sup>

#### HISTONE ACETYLTRANSFERASES AND COACTIVATOR COMPLEXES

In parallel with the developments in our understanding of HDACs, there have also been the recent identification and functional analysis of several human histone acetyltransferases (HATs<sup>70</sup>) and the mechanisms by which histone acetylation can activate transcription. Histone acetylation, at lysines within the N-terminal tails of H3 and H4, appears to be a prerequisite for the process of transcriptional activation in vivo.<sup>71</sup> The acetylation appears to mediate chromatin remodelling (which makes the chromatin more accessible to transcription factors) by the specific, targeted interaction of coactivator proteins that contain a bromodomain with acetyl lysines.<sup>72</sup> In particular, the bromodomain of a yeast nuclear HAT is able to bind in vitro to acetylated peptides of the H3 and H4 N-terminal tails<sup>73</sup> and the bromodomain is required for the subsequent recruitment and coordination of in vivo remodelling activity by the yeast SWI/SNF complex<sup>74</sup> (fig 2B).

Recent work has shown the intimate relationship between histone modifications and the processes of cell proliferation, cell differentiation, and oncogenesis. As discussed in previous sections, nuclear receptors have a key role in determining the balance of cell proliferation and cell differentiation in response to extracellular signals, such as the hormone retinoic acid. In the absence of ligand, the receptors remain constitutively bound to target promoters and recruit a transcriptional repressor complex (see above), which maintains the cell in a proliferating state. However, once the nuclear receptors bind the ligand, the repressor complex is replaced by an activator complex that induces cell differentiation (fig 2A). Components of the activator complexes include CREB binding

protein (CBP)<sup>75-76</sup> and the highly homologous protein p300,<sup>77-78</sup> both of which are now known to be histone acetyltransferases (HATs).<sup>79-80</sup> In addition to CREB and nuclear hormone receptors, the p300/CBP protein can also interact with other DNA binding transcription factors, such as c-Jun, c-Myb, c-Fos, and MyoD<sup>81</sup> (fig 2A), as well as p300/CBP associated factor (PCAF) that is itself a histone acetyltransferase.<sup>82</sup> The studies by Yang *et al*<sup>82</sup> also show that the E1A oncoprotein stimulates proliferation by disrupting the interaction of p300/CBP and PCAF, which would normally suppress cell growth. PCAF is also implicated in nuclear receptor coactivation.<sup>83-84</sup> Two additional nuclear hormone receptor coactivators, SRC-1 and ACTR, which are members of the p160 family, are also HATs<sup>85-86</sup> (see below). The human transcription factor TAF II 250, a component of the TFIID complex that recognises the TATA element at promoters, also contains HAT activity.<sup>28</sup>

A further level of complexity in the regulation of gene expression by HATs is that the enzymes can acetylate lysine groups of non-histone proteins. For example, p300/CBP and PCAF are able to acetylate transcription factors such as p53 and components of the general transcription machinery such as the TFIIE $\beta$  subunit.<sup>87-88</sup> Acetylation of both p53 and the haematopoietic transcription factor GATA-1 increased their DNA binding activities.<sup>87-89</sup> In the latter study, the acetylation of GATA-1 *in vivo* was implicated in the activation of target genes. A similar mechanism of regulation has been shown for the nuclear hormone receptor coactivator and acetyltransferase ACTR, which can itself be acetylated by p300/CBP.<sup>90</sup> As expected, hormone treatment of cells caused an increase in histone acetylation at receptor target genes. However, this effect was transient because the subsequent acetylation of ACTR led to dissociation of the receptor-coactivator complex and down regulation of transcription, and suggests that non-histone protein acetylation is the key element that autoregulates hormone induction. In a separate study, the acetylation of E2F1 by both PCAF and p300/CBP appears to enhance the function of this transcription factor,<sup>91</sup> which would presumably stimulate the transcription of target genes during S phase of the cell cycle. As discussed above, the E2F transcription factors repress transcription of target genes during G1 phase by interacting with the *Rb* tumour suppressor gene product pRb and histone deacetylases (HDACs). In addition, the *p53* tumour suppressor gene product has also been shown to repress transcription during apoptosis by recruiting the Sin3-HDAC complex,<sup>92</sup> and itself to become acetylated at defined lysine residues *in vivo*.<sup>93</sup> These observations suggest that transcriptional regulation involves the addition and removal of acetyl groups not only from histones but also from other nuclear proteins, which has important implications for the understanding of cell growth and oncogenesis.

#### HISTONE ACETYLTRANSFERASE AND LEUKAEMOGENIC FUSION PROTEINS

Transcriptional dysregulation by fusion proteins that contain histone acetyltransferases (HATs) has been implicated in leukaemogenesis<sup>94-95</sup> and in Rubinstein-Taybi syndrome (RTS). RTS is a developmental disorder in which patients have an increased incidence of malignancies.<sup>96</sup> Microdeletions, translocations, inversions, and point mutations in the CREB binding protein (CBP) gene have been identified in patients with RTS.<sup>96</sup> CBP translocations that correlate with acute myeloid leukaemia (AML) include fusions to the *MLL* (also known as *ALL-1*, see below) gene<sup>94</sup> and to the *MOZ* gene.<sup>95</sup> *MOZ* is itself a histone acetyltransferase<sup>95</sup> and a chromosomal translocation in AML can also fuse it to the nuclear receptor coactivator TIF2.<sup>97</sup> There are, as yet, no known chemical inhibitors of HATs that could therefore be assessed for AML therapy, in contrast to the retinoic acid and HDAC inhibitor treatments discussed above. It is likely that a nuclear HAT inhibitor will be isosteric for the acetate group, which would allow it to inactivate either the catalytic site or the bromodomain of the enzyme.

#### OTHER HISTONE MODIFICATIONS

The N-terminal tails of the core histones are subject to other post-translational modifications, which include phosphorylation, methylation, ADP ribosylation, and ubiquitination.<sup>98</sup> Phosphorylation of histone H3 at serine 10 has been the most extensively studied modification to date. It occurs during mitosis in many cells<sup>99</sup> as a transient and rapid response after mitogen stimulation, which correlates with the expression of *c-fos* and *c-jun*.<sup>100</sup> H3 phosphorylation in response to epidermal growth factor (EGF) appears to be mediated by the Rsk-2 kinase,<sup>101</sup> which is a member of the pp90<sup>sk</sup> (ribosomal S6 kinase) family that is implicated in cell proliferation and differentiation.<sup>102</sup> It is interesting to note that mutations in *Rsk-2* (but not in any other kinase in this family) are associated with Coffin-Lowry syndrome,<sup>103</sup> which is characterised by severe psychomotor retardation, facial and digital dysmorphism, and skeletal deformations. However, it remains unclear what role H3 phosphorylation has during cellular response to mitogens and if it has a direct involvement in gene regulation.

Methylation of histone H3 has been linked to gene activation by the p160 family of coactivators, which include the histone acetyltransferases SRC-1 and ACTR (see above). Both of these proteins, and a third member of this family called GRIP1, have been shown to interact with the coactivator associated arginine (R) methyltransferase (CARM1), which has extensive homology to other arginine methyltransferases.<sup>104</sup> CARM1 can also methylate histone H3 *in vitro*, and enhances the expression of a reporter gene in a transient transfection experiment. Methylation of histones, or other proteins in the transcription initiation complex, may therefore be a gene regulatory mechanism that cooperates with histone and protein acetylation.

### DNA methylation and gene silencing

At the level of DNA modifications, methylation of the C5 atom of cytosine residues is a powerful and prevalent mechanism for the repression and inactivation of genes. Methylation of promoter regions, on opposite DNA strands of the dinucleotide sequence CpG, correlate, in general, with transcriptional inhibition.<sup>105</sup> Hydrolytic deamination of 5'-methylcytosine to thymine residues generates T-G mispairs, which contribute to many germline point mutations associated with human genetic disease and other somatic mutations that lead to cancer.<sup>106-107</sup> For this reason, CpG dinucleotides tend not to be found in coding regions, but are clustered near the promoters of widely expressed housekeeping genes, but remain unmethylated at all levels of expression of the gene. CpG islands can become de novo methylated during normal development (to silence imprinted genes and the genes on the inactive X chromosome of female mammals), but the CpG islands of autosomal genes can also become methylated as a result of in vitro cell culture or neoplasia. It is possible that the silencing of certain tumour suppressor genes may, in part, be the consequence of de novo methylation of an adjacent CpG island. For example, the frequency with which promoter methylation contributes to the gene inactivation is 33% for *VHL* and 84% for *MLH1*, in von Hippel-Lindau (*VHL*) disease and microsatellite unstable colorectal tumours, respectively.<sup>108-109</sup> A causal link between promoter methylation and carcinogenesis is implied from studies of transgenic mice with targeted deletions of the DNA methyltransferase 1 (*Dnmt1*) gene, in which the formation of intestinal polyps was suppressed.<sup>110</sup> *Dnmt1* can also recruit histone deacetylase activity and can interact with HDAC1 in vitro.<sup>111</sup> *Dnmt1* methylates DNA containing hemimethylated CpG dinucleotides more efficiently than unmethylated DNA, and is therefore presumed to be the major maintenance methyltransferase in vivo.<sup>112</sup> Since *Dnmt1* protein colocalises with replication foci,<sup>112</sup> it will be interesting to see if HDACs have a particular role at the replication fork. Other mammalian DNA methyltransferases (*Dnmt3a* and *b*<sup>113</sup>) are likely to de novo methylate promoters, with *Dnmt3b* specifically required to methylate centromeric minor satellite (in mouse embryonic stem cells).<sup>114</sup> Mutations in one of the conserved catalytic domains of *DNMT3B*, which presumably cause a partial loss of function of the enzyme, are associated with ICF syndrome (for immunodeficiency, centromeric instability, facial anomalies).<sup>114-115</sup> ICF syndrome is characterised by immunological defects, hypomethylation, and instability of centromeric heterochromatin, and facial anomalies such as hypertelorism, epicanthic folds, and macroglossia.

The mechanism by which methylated promoters are inactivated has also become clearer and appears to involve a long term remodelling of the chromatin at the promoter. DNA methylation is able to reduce the binding affinity of sequence specific transcription factors or recruit sequence specific DNA binding pro-

teins, such as methylated DNA binding protein (MDBP),<sup>116-117</sup> which may act as transcriptional repressors. However, a more general process recruits sequence non-specific methyl-CpG binding proteins (MeCPs) that exclude transcription factors from the methylated promoter.<sup>10-118</sup> It is now clear that the key molecular mechanism that underlies this repression involves the recruitment of histone deacetylases (HDACs, see above and fig 1A). The MeCP2 protein contains a methyl binding domain (MBD), which allows it to bind to a single, symmetrically methylated CpG site and a transcriptional repression domain (TRD) which recruits the Sin3-HDAC corepressor complex.<sup>119</sup> This mechanism is now known to be implicated in repression by members of the MBD protein family, which were identified on the basis of homology with the MBD domain of MeCP2.<sup>120</sup> MBD2 forms the so called MeCP1 complex, together with HDAC1, HDAC2, and RbAp46 and 48,<sup>10-121</sup> and MBD3 is a component of the Mi2-NuRD deacetylase complex<sup>35-122</sup> (see above). It is interesting to note that MBD4 contains the canonical methyl CpG binding domain in addition to a thymine DNA glycosylase catalytic domain, which binds preferentially to methyl CpG-TpG mismatches in DNA.<sup>123</sup> It is therefore probable that the function of the MBD4 enzyme is to suppress mutation at methyl CpG, rather than to act as a transcriptional repressor. Frameshift mutations in *MBD4* that would cause truncation of the protein between the MBD and glycosylase domains, and hence cause a defect in mismatch repair, correlate with over 40% of microsatellite unstable sporadic colon cancers.<sup>124</sup>

Mutations in the *MECP2* gene, which encodes the X linked methyl CpG binding protein 2 (MeCP2, see above), are of particular clinical significance. Genetic linkage analysis has established that de novo missense mutations in the methyl CpG binding domain (MBD), and other mutations that disrupt the transcriptional repression domain (TRD), are a cause of Rett syndrome in about a quarter of the sporadic patients studied.<sup>125</sup> Rett syndrome is a progressive neurodevelopmental disorder that occurs almost exclusively in females, and is typified by the onset of autism, dementia, ataxia, and loss of purposeful hand movements from the ages of 6 to 18 months.<sup>126</sup> An additional study has made the suggestion that the effect of *MECP2* mutations may not be limited to Rett syndrome, since heterozygote females with skewed X inactivation patterns may have a mild disease phenotype.<sup>127</sup> However, it is clear that the mechanism that underlies the pathogenesis of Rett implicates a dysregulation in chromatin remodelling, although it is not yet known if a similar pathogenesis is seen for mutations in the MBD family, or their partners in multiprotein complexes.

### Chromatin remodelling and carcinogenesis

A further causal link between epigenetic dysregulation and carcinogenesis is provided

by defects in ATP utilising chromatin remodeling complexes. The role of these complexes is to physically reposition or disrupt nucleosomes by altering histone-DNA contacts.<sup>128 129</sup> The ATPase/helicase subunits of the complexes are members of three related families: homologues of yeast SWI2/SNF2 (for mating type switch/sucrose non-fermenting 2), the Mi-2 family (also known as the CHD family), and the ISWI (imitation SWI) family.

As discussed above, the dermatomyositis specific autoantigen and ATPase/helicase Mi-2 $\beta$  (also called CHD4) is a component of the NuRD complex<sup>33</sup> that contains the histone deacetylases HDAC1 and HDAC2 (fig 1C). This observation suggests that chromatin remodelling by the ATPase activity makes the histone tails more accessible to the NuRD deacetylases, with the subsequent formation of a repressive chromatin structure. However, neither the effect of NuRD mediated histone deacetylation on gene expression nor the targets of this type of chromatin remodelling are known, although the MBD3 component of the complex may recruit it to extensive, methylated regions of the genome such as heterochromatin. Since 15% to 30% of patients with dermatomyositis develop cancer,<sup>130 131</sup> it is therefore probable that changes in chromatin modification and remodelling can affect cell proliferation.

It is interesting to note that the Mi-2 $\beta$  protein contains two cysteine rich PHD (plant homeodomain)/zinc finger regions and two chromodomains, in addition to the helicase/ATPase domain. Homeodomains and chromodomains are common features of other transcriptional regulators that bind to chromatin,<sup>72 132</sup> which include the *DNMT3* family of DNA methyltransferases<sup>112</sup> and ALL-1 (also known as MLL, HRX, or HTRX, see below).<sup>133</sup> Another such protein is ATRX (for  $\alpha$  thalassaemia/retardation on the X chromosome) which, like Mi2 $\beta$ , also contains PHD-like fingers and other domains that classify it as a member of the ATPase/helicase superfamily. The functional importance of the PHD-like fingers is shown by the observation that two thirds of all mutations that cause ATRX syndrome lie in this region.<sup>134</sup> ATRX syndrome comprises a severe form of mental retardation, characterised by the presence of  $\alpha$  thalassaemia, urogenital abnormalities, and facial dysmorphism.<sup>135 136</sup> In view of the interaction of Mi2 $\beta$  protein with HDAC1,<sup>33</sup> it is probable that PHD-like domains in other transcriptional regulators also mediate the same interaction. In addition, mutations in *ATRX* are associated with changes in DNA methylation patterns at highly repeated sequences, such that rDNA repeat arrays are hypomethylated whereas others (the Y specific repeat DYZ2) are hypermethylated.<sup>137</sup> This observation implies a link between chromatin remodelling, mediated by the ATRX protein, and the DNA methylation system. However, it is unclear if ATRX functions as a transcriptional coactivator (similar to the SWI2/SNF2 proteins) to increase the expression of a component of the DNA methylation system, or if it

increases the accessibility of chromatin to a DNA methyltransferase.

The human SWI/SNF complex has been found to act as a coactivator for several nuclear receptors<sup>138</sup> and appears to be both recruited to specific regions of chromatin by DNA binding proteins and to remodel promoter regions to facilitate the binding of other factors.<sup>129 139</sup> The two human homologues of SWI/SNF2, BRG-1 and hBRM, are also implicated in transcriptional repression, since both can interact with the tumour suppressor gene product Rb.<sup>20 140</sup> As discussed above, Rb regulates cell cycle progression by inhibiting the activity of the transcriptional activator E2F and recruiting histone deacetylases. Transient transfection of BRG-1 or hBRM into cell lines that do not express these proteins but that do express Rb leads to growth arrest<sup>29</sup> and, furthermore, fibroblasts transformed with *ras* and lacking endogenous expression of BRM revert to a flattened, growth arrested phenotype after reintroduction of *hBRM*.<sup>140</sup> These observations establish the link between chromatin remodelling by SWI/SNF and control of the cell cycle. A further connection is provided by another subunit of the SWI/SNF complex, called hSNF5/INI1. Genetic linkage has identified biallelic deletions or mutations in the hSNF5/INI1 gene to be responsible for malignant rhabdoid tumours, which are very aggressive cancers of early childhood that tend to occur in the kidney, brain, and soft tissues.<sup>141</sup> Another study has shown that deletions of hSNF5/INI1 can be acquired during leukaemogenesis in patients with chronic myeloid leukaemia.<sup>142</sup>

#### Maintenance of chromatin states and carcinogenesis

Recent work has shown that the maintenance of active and inactive chromatin states is an important determinant of gene expression. In *Drosophila*, the coordinated expression of the homeotic genes determines segmentation and body plan along the anterior-posterior axis. The maintenance of this expression throughout development is mediated by the Polycomb-group (Pc-G) repressor proteins and the trithorax-group (trx-G) activator proteins.<sup>143</sup> Many of the polycomb- and trithorax-group proteins contain the SET domain (for Suvar3-9, Enhancer-of-zeste, Trithorax), that is conserved in a number of mammalian homologues. ALL-1, for example, is the human homologue of *Drosophila* Trithorax protein, which is a positive regulator of homeotic gene expression. A similar role is implied for the mammalian MLL/ALL-1 because heterozygous *mll*<sup>+/−</sup> mice have defects in axial skeletal development and haematopoiesis, which arise from alterations in the pattern of *Hox* gene expression.<sup>144</sup> The *ALL-1* gene, at the 11q23 locus, is one of the most common targets of chromosomal translocations in acute lymphocytic leukaemia and other acute leukaemias,<sup>145</sup> and there are at least 30 partner genes that produce in frame leukogenic fusion proteins with ALL-1/MLL, including the histone acetyltransferase CBP<sup>94</sup> (see above). In general, the C-terminal SET domain of

ALL-1/MLL is lost during chromosomal translocation. It is interesting to note that the hSNF5/INI1 component of the SWI/SNF complex (see above) has been shown to interact with the SET domain of ALL-1.<sup>146</sup> One of the consequences of ALL-1/MLL translocations would be the inability to recruit SWI/SNF, and it is therefore possible that the transformation of haematopoietic cells involves the dysregulation of chromatin remodelling, as well as the aberrant expression of MLL/ALL-1 target genes.

Mammalian polycomb-group homologues are thought to be negative regulators of homeotic gene expression. EED (for embryonic ectoderm development) is required at a very early stage in embryonic development and is the only known homologue of the *Drosophila* extra sex combs (esc) Pc-G protein. Disruption of the *eed* gene in mice causes defects in anterior mesoderm production, followed by death at day 8.5 of gestation.<sup>147</sup> In addition, the histone deacetylases HDAC1 and HDAC2 have been shown to interact with EED, but not with other vertebrate Pc-G proteins.<sup>148</sup> This result again underlines the complex and subtle interplay between the separate mechanisms of gene regulation.

### Conclusion

In the past few years, the exciting progress in the field of gene regulation has made it clear that chromatin is not just a static structure, but that it has a pivotal role in regulating transcription. Chromatin has a dynamic structure that can be modulated during cell differentiation and transformation, and the nucleosome is a substrate that can both receive and transmit intracellular signals. In addition, chromatin has the capacity to encode epigenetic information on levels of gene expression, which is independent of the genetic information encoded by the sequence of genes.<sup>149</sup> A parallel development is the realisation that many transcription factors can function by recruiting large, multi-protein complexes that mediate several types of chromatin modification and remodelling events. It is therefore not surprising that mutations that cause loss or perturbation of chromatin modification and remodelling activities will cause changes in gene expression levels. This points to abnormal epigenetic regulation as a general mechanism that underlies human carcinogenesis and the pathogenesis of other genetic diseases (see table 1 for a summary). For example, the types of mutations that are associated with most classes of acute myeloid leukaemia are typified by balanced chromosome translocations that result in the expression of chimaeric proteins. Most of these chimaeric proteins involve the in frame fusion of transcriptional regulator that results in transcriptional dysregulation. Some of the proteins that mediate chromatin modification and remodelling are therefore novel molecular targets for future treatments of cancer and other genetic diseases.

One of the most intriguing aspects of this recent work is the probable interplay between modification and remodelling events. Future

work will undoubtedly uncover further mechanistic links between distinct gene regulation systems. But a hint of this interplay is seen with the possible interactions of histone deacetylase. As discussed above, HDAC1 and HDAC2 can interact with the DNA methyltransferase Dnmt1, the polycomb-like protein EED, and the ATPase/helicase Mi-2 $\beta$ . To add to this complexity, it is not known if other histone and protein post-translational modifications (notably histone phosphorylation and methylation) can modulate the effects of chromatin modification and remodelling, or if they participate in other gene regulation systems of their own. Another important aspect is a description and understanding of the signal transduction pathways that use chromatin as a target, and how these signals can mediate changes in gene expression. For example, a very recent development has shown that recombinant yeast and mouse Sir2 proteins, and other yeast Sir2 homologues, are novel, NAD dependent histone deacetylases.<sup>150 151</sup> In yeast, Sir2 is a mediator of transcriptional silencing at the heterochromatic regions associated with silent mating loci, telomeres, and ribosomal DNA.<sup>152</sup> However, the absolute requirement of NAD for the deacetylation reaction suggests that this form of chromatin modification can be regulated by the metabolic levels of NAD and NADH, and hence by calorific intake.<sup>153</sup>

The author would like to thank Doug Higgs, Institute of Molecular Medicine, Oxford and members of the Chromatin and Gene Expression Group for suggestions and critical evaluation of the manuscript.

- Kornberg RD, Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. *Cell* 1999;**98**:285-94.
- Paranjape SM, Kamakaka R, Kadonaga J. Role of chromatin structure in the regulation of transcription by RNA polymerase II. *Annu Rev Biochem* 1994;**63**:265-97.
- Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. *Nature* 1997;**389**:251-60.
- Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. *Annu Rev Biochem* 1998;**67**:545-79.
- Usachenko SI, Bavykin SG, Gavin IM, Bradbury EM. Rearrangement of the histone H2A C-terminal domain in the nucleosome. *Proc Natl Acad Sci USA* 1994;**91**:6845-9.
- Walker IO. Differential dissociation of histone tails from core chromatin. *Biochemistry* 1984;**23**:5622-8.
- Luger K, Richmond TJ. The histone tails of the nucleosome. *Curr Opin Genet Dev* 1998;**8**:140-6.
- Johnson CA, Turner BM. Histone deacetylases: complex transducers of nuclear signals. *Semin Cell Develop Biol* 1999;**10**:179-88.
- Zhang Y, Iratni R, Erdjument-Bromage H, Tempst P, Reinberg D. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex. *Cell* 1997;**89**:357-64.
- Ng HH, Bird A. Histone deacetylases: silencers for hire. *Trends Biochem Sci* 2000;**25**:121-6.
- Struhl K. Histone acetylation and transcriptional regulatory mechanisms. *Genes Dev* 1998;**12**:599-606.
- Henriksson M, Luscher B. Proteins of the Myc network: essential regulators of cell growth and differentiation. *Adv Cancer Res* 1996;**68**:109-82.
- Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultschi AI, DePinho RA. An amino terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. *Cell* 1995;**80**:767-76.
- Sommer A. Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity. *Curr Biol* 1997;**7**:357-65.
- Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. *Nature* 1997;**387**:43-8.
- Alland L, Muhle R, Hou HJ, Potes J, Chin L, Schreiber-Agus N, DePinho R. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. *Nature* 1997;**387**:49-55.



- 17 Nagy L, Kao H, Chakravarti D, Lin R, Hassig C, Ayer D, Schreiber S, Evans R. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A and histone deacetylase. *Cell* 1997;**89**:373-80.
- 18 Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. *Curr Opin Genet Dev* 1999;**9**:140-7.
- 19 Grunstein M. Histone acetylation in chromatin structure and transcription. *Nature* 1997;**389**:349-52.
- 20 Brehm A, Kouzarides T. Retinoblastoma protein meets chromatin. *Trends Biochem Sci* 1999;**24**:142-5.
- 21 Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. *Cell* 1992;**70**:993-1006.
- 22 Weinberg RA. E2F and cell proliferation: a world turned upside down. *Cell* 1996;**85**:457-9.
- 23 Kaelin WG, Ewen ME, Livingston DM. Definition of the minimal simian virus 40 large T- and adenovirus E1A-binding domain in the retinoblastoma gene product. *Mol Cell Biol* 1990;**10**:3761-9.
- 24 Luo RX, Postigo AA, Dean DC. Rb interacts with histone deacetylase to repress transcription. *Cell* 1998;**92**:463-73.
- 25 Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. *Nature* 1998;**391**:597-601.
- 26 Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. *Nature* 1998;**391**:601-5.
- 27 Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A, Trouche D. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase. *Proc Natl Acad Sci USA* 1998;**95**:10493-8.
- 28 Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T, Workman J, Wang L, Berger SL, Kouzarides T, Nakatani Y, Allis CD. The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. *Cell* 1996;**87**:1261-70.
- 29 Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J, Begemann M, Crabtree GR, Goff SP. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. *Cell* 1994;**79**:119-30.
- 30 Roth SY, Allis CD. Histone acetylation and chromatin assembly: a single escort, multiple dances? *Cell* 1996;**87**:5-8.
- 31 Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. *Science* 1996;**272**:408-11.
- 32 Verrault A, Kaufman PD, Kobayashi R, Stillman B. Nucleosomal DNA regulates the core-histone binding subunit of the human Hat1 acetyltransferase. *Curr Biol* 1998;**8**:96-108.
- 33 Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. *Cell* 1998;**95**:279-89.
- 34 Seelig H, Moosbrugger I, Ehrfeld H, Fink T, Renz M, Genth E. The major Mi-2 autoantigen is a presumed helixase involved in transcriptional activation. *Arthritis Rheum* 1995;**38**:1389-99.
- 35 Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. *Genes Dev* 1999;**13**:1924-35.
- 36 Toh Y, Pencil SD, Nicolson GL. A novel candidate metastasis-associated gene, *mta1*, differentially expressed in highly metastatic mammary adenocarcinoma cell lines: cDNA cloning, expression and protein analysis. *J Biol Chem* 1994;**269**:22958-63.
- 37 Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E, Winandy S, Viel A, Sawyer A, Ikeda T, Kingston R, Georgopoulos K. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. *Immunity* 1999;**10**:345-55.
- 38 Koipally J, Renold A, Kim J, Georgopoulos K. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. *EMBO J* 1999;**18**:3090-100.
- 39 Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. *Nature* 1998;**391**:811-14.
- 40 Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Ciocce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. Fusion proteins of the retinoic acid receptor- $\alpha$  recruit histone deacetylase in promyelocytic leukaemia. *Nature* 1998;**391**:815-18.
- 41 Redner RL, Wang J, Liu JM. Chromatin remodelling and leukaemia: new therapeutic paradigms. *Blood* 1999;**94**:417-28.
- 42 Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG. Acute promyelocytic leukemia: from genetics to treatment. *Blood* 1994;**83**:10-25.
- 43 Golub TR. The genetics of AML: an update. *Blood* 1999;(suppl):102-11.
- 44 Casini T, Pelicci PG. A function of p21 during promyelocytic leukaemia cell differentiation independent of CDK inhibition and cell cycle arrest. *Oncogene* 1999;**18**:3235-43.
- 45 Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. *Nature* 1995;**377**:552-7.
- 46 Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, DeBlasio A, Miller WH Jr, Zelenetz AD, Willman CL, Chen Z, Chen S-J, Zent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S. Clinical and molecular characterisation of a rare syndrome of acute promyelocytic leukaemia associated with translocation (11;17) *Blood* 1995;**85**:1083-94.
- 47 Hong SH, David G, Wong CW, Dejean A, Privalsky ML. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukaemia. *Proc Natl Acad Sci USA* 1997;**94**:9028-33.
- 48 Li JY, English MA, Ball HJ, Yeyati PL, Waxman S, Licht JD. Sequence-specific DNA binding and transcriptional regulation by the promyelocytic leukemia zinc finger protein. *J Biol Chem* 1997;**272**:22447-55.
- 49 Dhordain P, Albagli O, Lin RJ, Ansieau S, Queif S, Leutz A, Kerckaert JP, Evans RM, LePrince D. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. *Proc Natl Acad Sci USA* 1997;**94**:10762-7.
- 50 Deltour S, Guerardel C, LePrince D. Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFDP-B. *Proc Natl Acad Sci USA* 1999;**96**:14831-6.
- 51 Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. *J Natl Cancer Inst* 1998;**90**:1621-5.
- 52 Candido E, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. *Cell* 1978;**14**:105-13.
- 53 Sealy L, Chalkley R. The effect of sodium butyrate on histone modifications. *Cell* 1978;**14**:115-21.
- 54 Yoshida M, Hoshikawa Y, Koseki K, Mori K, Beppu T. Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. *J Antibiot* 1990;**43**:1101-6.
- 55 Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkin RA, Marks PA. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. *Proc Natl Acad Sci USA* 1998;**95**:3003-7.
- 56 Hassig CA, Tong JK, Fleischer TC, Owa T, Grable PG, Ayer DE, Schreiber SL. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. *Proc Natl Acad Sci USA* 1998;**95**:3519-24.
- 57 Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkin RA, Marks PA, Breslow R, Pavletic NP. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. *Nature* 1999;**401**:188-93.
- 58 Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, Matsumoto K, Ishii K, Uotani N, Nakai H. Isolation and structural elucidation of new cyclohexapeptides, trapoxins A and B, having detransformation activities as antitumour agents. *J Antibiot* 1990;**43**:1524-32.
- 59 Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T. Trapoxin, an antitumour cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. *J Biol Chem* 1993;**268**:22429-35.
- 60 Brosch G, Ransom R, Lechner T, Walton JD, Loidl P. Inhibition of maize histone deacetylases by HC toxin, the host-specific toxin of *Cochliobolus carbonum*. *Plant Cell* 1995;**7**:1941-50.
- 61 Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL. Depudicidin induces morphological reversal of transformed fibroblasts via the inhibition of histone deacetylase. *Proc Natl Acad Sci USA* 1998;**95**:3356-61.
- 62 Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelatinase expression by inhibiting histone deacetylase in human carcinoma cell lines. *Exp Cell Res* 1994;**214**:189-97.
- 63 Yoshida M, Nomura S, Beppu T. Effects of trichostatin on differentiation of murine erythroleukemia cells. *Cancer Res* 1987;**47**:3688-91.
- 64 Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumour antibiotic, is a novel histone deacetylase inhibitor. *Exp Cell Res* 1998;**241**:126-33.
- 65 Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. *BioEssays* 1995;**17**:423-30.
- 66 Wang J, Sauntharajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukaemia cells. *Cancer Res* 1999;**59**:2766-9.
- 67 Archer SY, Hodin RA. Histone acetylation and cancer. *Curr Opin Genet Develop* 1999;**9**:171-4.
- 68 Archer SY, Meng S, Shei A, Hodin RA. p21/WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells. *Proc Natl Acad Sci USA* 1998;**95**:6791-6.
- 69 Sambucetti LC, Fischer D, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. *J Biol Chem* 1999;**274**:34940-7.
- 70 Grant PA, Berger SL. Histone acetyltransferase complexes. *Semin Cell Develop Biol* 1999;**10**:169-77.
- 71 Kuo MH, Zhou J, Jambeck P, Churchill ME, Allis CD. Histone acetyltransferase activity of yeast Gcn5p is required

- for the activation of target genes *in vivo*. *Genes Dev* 1998;12:627-39.
- 72 Winston F, Allis CD. The bromodomain: a chromatin-targeting module? *Nat Struct Biol* 1999;6:601-4.
- 73 Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. *Nature* 1999;399:491-6.
- 74 Syntichaki P, Topalidou I, Thireos G. The Gcn5 bromodomain co-ordinates nucleosome remodelling. *Nature* 2000;404:414-17.
- 75 Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Glass B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* 1996;85:403-14.
- 76 Aarnisalo P, Palvimo JJ, Janne OA. CREB-binding protein in androgen receptor-mediated signalling. *Proc Natl Acad Sci USA* 1998;95:2122-7.
- 77 Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM. Role of CBP/p300 in nuclear receptor signalling. *Nature* 1996;383:99-103.
- 78 Kraus WL, Kadonaga JT. p300 and oestrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. *Genes Dev* 1998;12:331-42.
- 79 Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* 1996;87:953-9.
- 80 Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. *Nature* 1996;384:641-3.
- 81 Janknecht R, Hunter T. Versatile molecular glue: transcriptional control. *Curr Biol* 1996;6:951-4.
- 82 Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* 1996;382:319-24.
- 83 Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K. The histone acetylase PCAF is a nuclear receptor coactivator. *Genes Dev* 1998;12:1638-51.
- 84 Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. *Science* 1998;279:703-7.
- 85 Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Steroid receptor coactivator-1 is a histone acetyltransferase. *Nature* 1997;389:194-8.
- 86 Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with PCAF and CBP/p300. *Cell* 1997;90:569-80.
- 87 Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. *Cell* 1997;90:595-606.
- 88 Imhof A, Yang XJ, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H. Acetylation of general transcription factors by histone acetyltransferases. *Curr Biol* 1997;7:689-92.
- 89 Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. *Nature* 1998;396:594-8.
- 90 Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. *Cell* 1999;98:675-86.
- 91 Martinez-Balbás MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F1 activity by acetylation. *EMBO J* 2000;19:662-71.
- 92 Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. *Genes Dev* 1999;13:2490-501.
- 93 Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL. p53 sites acetylated *in vitro* by PCAF and p300 are acetylated *in vivo* in response to DNA damage. *Mol Cell Biol* 1999;19:1202-9.
- 94 Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukaemia with a t(11;16)(q23;p13.3). *Proc Natl Acad Sci USA* 1997;94:8732-7.
- 95 Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Distche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. *Nat Genet* 1996;14:33-41.
- 96 Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, Tommerup N, van Ommen GJ, Goodman RH, Peters DJ, Breuning MH. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. *Nature* 1995;376:348-51.
- 97 Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukaemia. *Blood* 1998;91:3127-33.
- 98 Wu RS, Panusz HT, Hatch CL, Bonner WM. Histones and their modifications. *CRC Crit Rev Biochem* 1986;20:201-63.
- 99 Bradbury EM. Reversible histone modifications and the chromosome cell cycle. *BioEssays* 1992;14:9-16.
- 100 Thomson S, Mahadevan L, Clayton AL. MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction. *Semin Cell Develop Biol* 1999;10:205-14.
- 101 Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L, Jacquot S, Hanauer A, Allis CD. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. *Science* 1999;285:886-91.
- 102 Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. *Proc Natl Acad Sci USA* 1993;90:5889-92.
- 103 Trivier E, DeCesare D, Jacquot S, Pannetier S, Zackai E, Young I, Mandel JL, Sassone-Corsi P, Hanauer A. Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. *Nature* 1996;384:567-70.
- 104 Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR. Regulation of transcription by a protein methyltransferase. *Science* 1999;284:2174-7.
- 105 Bird A. The essentials of DNA methylation. *Cell* 1992;70:5-8.
- 106 Yang A, Jones P, Shibata A. The mutational burden of 5-methylcytosine. In: Russo V, Martienssen R, Riggs A, eds. *Epigenetic mechanisms of gene regulation*. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1996:77-94.
- 107 Jones PA, Laird PW. Cancer epigenetics comes of age. *Nat Genet* 1999;21:163-7.
- 108 Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER. Somatic inactivation of the *VHL* gene in Von Hippel-Lindau disease tumours. *Am J Hum Genet* 1997;60:765-71.
- 109 Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. *Proc Natl Acad Sci USA* 1998;95:6870-5.
- 110 Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. *Cell* 1995;81:197-205.
- 111 Fuks F, Burgers WA, Brehm A, Hughes-Davies L, Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. *Nat Genet* 2000;24:88-91.
- 112 Bestor TH, Verdine GL. DNA methyltransferases. *Curr Opin Cell Biol* 1994;6:380-9.
- 113 Okano M, Xie S, Li E. Cloning and characterisation of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat Genet* 1998;19:219-20.
- 114 Okano M, Bell DW, Haber DA and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 1999;99:247-57.
- 115 Xu GL, Bestor TH, Bourc'his D, Hsieh CL, Tommerup N, Bugge M, Hulten M, Qu X, Russo JJ, Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. *Nature* 1999;402:187-91.
- 116 Prendergast GC, Ziff EB. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. *Science* 1991;251:186-9.
- 117 Zhang XY, Ehrlich KC, Wang RY, Ehrlich M. Effect of site-specific DNA methylation and mutagenesis on recognition by methylated DNA-binding protein from human placenta. *Nucleic Acids Res* 1985;14:8387-97.
- 118 Bird A, Wolffe A. Methylation-induced repression—belts, braces and chromatin. *Cell* 1999;99:451-4.
- 119 Nan X, Ng HH, Johnson CA, Laherty CA, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature* 1998;393:386-9.
- 120 Hendrich B, Bird A. Identification and characterisation of a family of mammalian methyl-CpG-binding proteins. *Mol Cell Biol* 1998;18:6538-47.
- 121 Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, Tempst P, Reinberg D, Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. *Nat Genet* 1999;23:58-61.
- 122 Wade PA, Geggion A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. *Nat Genet* 1999;23:62-6.
- 123 Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. *Nature* 1999;401:301-4.
- 124 Bader S, Walker M, Hendrich B, Bird A, Bird C, Hooper M, Wyllie A. Somatic frameshift mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. *Oncogene* 1999;18:8044-7.
- 125 Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked *MECP2*, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999;23:185-8.
- 126 Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. *Ann Neurol* 1983;14:471-9.
- 127 Wan M, Lee S, Zhang X, Houwink-Manville I, Song H, Amir R, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY, Schanen NC, Francke U. Rett syndrome and beyond: recurrent spontaneous and familial *MECP2* mutations at CpG hotspots. *Am J Hum Genet* 1999;65:1520-9.
- 128 Varga-Weisz PD, Becker PB. Chromatin-remodelling factors: machines that regulate? *Curr Opin Cell Biol* 1998;10:346-53.

- 129 Tyler JK, Kadonaga JT. The "dark side" of chromatin remodelling: repressive effects on transcription. *Cell* 1999;99:443-6.
- 130 Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. *J Rheumatol* 1995;22:1300-3.
- 131 Shorr AF, Yacavone M, Seguin S, Jackson LW, Dennis GJ. Dermatomyositis and malignant melanoma. *Am J Med Sci* 1997;313:249-51.
- 132 Aasland R, Gibson TJ, Stewart AF. The PHD finger: implications for chromatin-mediated transcriptional regulation. *Trends Biochem Sci* 1995;20:56-9.
- 133 Ma Q, Alder H, Nelson KK, Chatterjee D, Gu Y, Nakamura T, Canaani E, Croce CM, Siracusa LD, Buchberg AM. Analysis of the murine All-1 gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases. *Proc Natl Acad Sci USA* 1993;90:6350-4.
- 134 Gibbons RJ, Bachoo S, Picketts DJ, Aftimos S, Asenbauer B, Bergoffen J, Berry SA, Dahl N, Fryer A, Keppler K, Kurosawa K, Levin ML, Masuno M, Neri G, Pierpont ME, Slaney SF, Higgs DR. Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain. *Nat Genet* 1997;17:146-8.
- 135 Chudley AE, Lowry RB. X linked alpha thalassaemia/mental retardation (ATR-X) syndrome. *J Med Genet* 1992;29:357.
- 136 Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassaemia (ATR-X syndrome). *Cell* 1995;80:837-45.
- 137 Gibbons RJ, McDowell TL, Raman S, O'Rourke DM, Garrick D, Ayyub H, Higgs DR. Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. *Nat Genet* 2000;24:368-71.
- 138 Muchardt C, Yaniv M. A human homologue of *Saccharomyces cerevisiae* SNF2/SWI2 and *Drosophila* brm genes potentiates transcriptional activation by the glucocorticoid receptor. *EMBO J* 1993;12:4279-90.
- 139 Kingston RE, Bunker CA, Imbalzano AN. Repression and activation by multiprotein complexes that alter chromatin structure. *Genes Dev* 1996;10:905-20.
- 140 Muchardt C, Yaniv M. The mammalian SWI/SNF complex and the control of cell growth. *Semin Cell Develop Biol* 1999;10:189-95.
- 141 Versteeg I, Sevenet N, Lange J, Rousseau-Merck MF, Ambos P, Handgretinger R, Aurias A, Delattre O. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature* 1998;394:203-6.
- 142 Grand F, Kulkarni S, Chase A, Goldman JM, Gordon M, Cross NC. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukaemia. *Cancer Res* 1999;59:3870-4.
- 143 Pirrotta P. Pc-G complexes and chromatin silencing. *Curr Opin Genet Dev* 1997;7:249-58.
- 144 Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. *Nature* 1995;378:505-8.
- 145 Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemins-van der Poel S, Kaneko Y, Morgan R, Sandberg AA, Chaganti RS, Larson RA, Le Beau MM, Diaz MO, Rowley JD. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukaemias with 11q23 chromosomal translocations. *N Engl J Med* 1993;329:909-14.
- 146 Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E. The C-terminal SET domains of ALL-1 and Trithorax interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. *Proc Natl Acad Sci USA* 1998;95:4152-7.
- 147 Faust C, Schumacher A, Holdener B, Magnuson T. The eed mutation disrupts anterior mesoderm production in mice. *Development* 1995;121:273-85.
- 148 van der Vlag J, Otte AP. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. *Nat Genet* 1999;23:474-8.
- 149 Turner BM. Histone acetylation and epigenetic code. *BioEssays* (in press).
- 150 Imai SI, Armstrong CM, Kaerberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. *Nature* 2000;403:795-800.
- 151 Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L, Sternglanz R. The silencing protein SIR2 and its homologues are NAD-dependent protein deacetylases. *Proc Natl Acad Sci USA* 2000;97:5807-11.
- 152 Sherman JM, Pillus L. An uncertain silence. *Trends Genet* 1997;13:308-13.
- 153 Guarente L. Sir2 links chromatin silencing, metabolism and aging. *Genes Dev* 2000;14:1021-6.